• Over 90% of patients also received cisplatin, carboplatin-paclitaxel, or cetuximab chemotherapy. (medscape.com)
  • We explored efficacy and safety of adding ganitumab, a monoclonal antibody targeting IGF-1R, to carboplatin/paclitaxel (CP) chemotherapy in patients with primary EOC. (uni-muenchen.de)
  • Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (cincinnatichildrens.org)
  • We conducted a phase II study of combination chemotherapy with paclitaxel (Pac) and irinotecan (CPT) to determine the effects and toxicities in patients 70 years or older with unresectable non-small cell lung cancer (NSCLC). (oldcitypublishing.com)
  • Omitting bolus fluorouracil, reducing doses, eliminating drugs that cause excessive toxicity, and using chemotherapy holidays have been found to increase the tolerability of this regimen. (jnccn.org)
  • combined with bevacizumab/carboplatin/ paclitaxel (ABCP) versus bevacizumab/chemotherapy for patients with metastatic nonsquamous NSCLC. (jnccn.org)
  • Based on preclinical studies, it appears that Opaxio is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed, allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. (salesandmarketingnetwork.com)
  • The paper details the protective action of both molecules against this exchanger, known to increase calcium levels in patients taking the chemotherapy drug paclitaxel. (biospace.com)
  • Hypothesize that lower scores in functional status assessment tool - instrumental activities of daily living (IADL) will correlate with higher rates of grade 3 or higher chemotherapy toxicity. (iu.edu)
  • Evaluate the association between baseline and change during treatment of skeletal muscle index (SMI) and intermuscular adipose tissue (IMAT) and rates of grade 3 or higher chemotherapy toxicity experienced on treatment. (iu.edu)
  • Evaluation of the correlation between base line levels of biomarkers of aging (CRP and IL-6) and rates of grade 3 or higher chemotherapy toxicity during therapy. (iu.edu)
  • However, the trial also showed that IP chemotherapy resulted in increased toxicity compared with IV chemotherapy. (medscape.com)
  • [ 2 ] and paclitaxel (Taxol). (medscape.com)
  • But a study by the Eastern Cooperative Oncology Group (ECOG) now suggests the risk is small when trastuzumab is combined with paclitaxel (Taxol), and, for the most part, cardiac changes are reversible. (cancernetwork.com)
  • Opaxio (paclitaxel poliglumex, CT-2103), is an investigational, biologically enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol , to a biodegradable polyglutamate polymer, which results in a new chemical entity. (salesandmarketingnetwork.com)
  • The greatest increase in solubility was for the cancer drug paclitaxel - sold as Taxol. (chemistryworld.com)
  • Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. (nih.gov)
  • Treatment is to continue until disease progression, unacceptable toxicity or completion of all protocol treatment. (cincinnatichildrens.org)
  • Treatment is repeated every 2 weeks for up to 7 courses in the absence of disease progression and unacceptable toxicity. (knowcancer.com)
  • Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. (iu.edu)
  • Kattan JG, Boutros CY, Farhat FS, Chahine GY, Musallam KM, Ghosn MG. Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer. (jcancer.org)
  • In this study, we evaluate the efficacy and safety of gemcitabine and carboplatin followed sequentially by paclitaxel in 27 patients with advanced transitional cell carcinoma. (jcancer.org)
  • This phase II multicentre study was based on the doublet gemcitabine 800 mg/m2 and carboplatin area under the concentration-time curve 2 on days 1 and 8 every 21 days for 4 cycles, followed sequentially by paclitaxel 60 mg/m 2 /w for 12 consecutive weeks. (jcancer.org)
  • the sequential approach of treatment for advanced urothelial cancer using gemcitabine and carboplatine followed by paclitaxel seems to be a safer alternative to the combined triplet, but due to the limited number of patients this study failed to improve outcome. (jcancer.org)
  • Several systemic therapies, such as oxaliplatin + irinotecan/fluorouracil/leucovorin (FOLFIRINOX) and gemcitabine + nab-paclitaxel, have shown activity in the adjuvant and neoadjuvant settings. (jnccn.org)
  • Another frequently used regimen, nab-paclitaxel + gemcitabine, was evaluated in the global phase III MPACT trial. (jnccn.org)
  • Patients with an ECOG performance status of 2 were randomly assigned to receive gemcitabine alone or in combination with nab-paclitaxel. (jnccn.org)
  • This is the trial that put gemcitabine and nab-paclitaxel into [the NCCN Guidelines]. (jnccn.org)
  • According to Dr. Tempero, compared with FOLFIRNOX, gemcitabine + nab-paclitaxel demonstrates an improved toxicity profile. (jnccn.org)
  • The combination of gemcitabine, erlotinib, and S-1 provided an acceptable toxicity profile and modest clinical benefits in patients with advanced pancreatic cancer. (jcancer.org)
  • ARM A: Patients receive gemcitabine intravenously (IV) over 30 minutes and nab-paclitaxel IV over 30 minutes on day 1. (iu.edu)
  • The current chemotherapeutic regimens for pancreatic cancer, including gemcitabine, FOLFIRNOX, and nab-paclitaxel, only provide limited benefits to the patients, due to low response rate and/or intolerable toxicities. (ku.edu)
  • CAR-T therapy can induce rapid and durable clinical responses but is associated with unique acute toxicities. (nature.com)
  • Daily adaptive radiotherapy can improve salivary gland sparing and lead to fewer acute toxicities for patients with squamous cell head and neck cancer, according to results from a randomized trial presented at the American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting. (medscape.com)
  • However, acute toxicities are also increased. (medscape.com)
  • Overall, the researchers concluded that for patients with head and neck cancer, DART "may improve physician- and patient-reported acute toxicity profiles, albeit with increased resource utilization. (medscape.com)
  • 165 patients assessable for toxicity. (uni-muenchen.de)
  • This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. (nih.gov)
  • ECOG 2198 examined the cardiac effects of paclitaxel plus trastuzumab (TH) given prior to doxorubicin plus cyclophosphamide (AC) in 234 HER-2-positive (2+ or 3+) stage II breast cancer patients. (cancernetwork.com)
  • Patients were randomized to paclitaxel 175 mg/m² every 3 weeks for 4 weeks plus trastuzumab for 10 weeks followed by AC (60/600 mg/m²) every 3 weeks for 4 weeks, or to the same treatment with trastuzumab given for 52 weeks. (cancernetwork.com)
  • Determine the toxicity of amifostine in these patients. (knowcancer.com)
  • Patients receive paclitaxel by continuous infusion on days 0-3. (knowcancer.com)
  • Of the hematological toxicities, grade 4 neutropenia was observed in 23.8% of the patients. (oldcitypublishing.com)
  • Of the non-hematological toxicities, grade 3 or 4 fatigue, anorexia and nausea were observed in 5, 3 and 4 patients, respectively. (oldcitypublishing.com)
  • The Pac plus CPT regimen is feasible and active with moderate toxicity for elderly patients with NSCLC. (oldcitypublishing.com)
  • Toxicities were mainly hematologic, including Grade 3 neutropenia and anemia in 3 patients. (jcancer.org)
  • However, nine of the first 17 patients developed grade 3 or higher neutropenia, and four developed grade 3 or higher thrombocytopenia while on weekly panitumumab, nab-paclitaxel, and carboplatin. (medpagetoday.com)
  • Nine patients died on study (one of which was deemed to be treatment related), and three patients ceased treatment due to toxicity or distant metastasis. (medpagetoday.com)
  • Toxicities were evaluated in 36 patients, and the responses were evaluated in 32 patients. (jcancer.org)
  • Common adverse reactions when used in combination with carboplatin and paclitaxel in patients with dMMR/MSI-H endometrial cancer include rash, diarrhea, hypothyroidism, and hypertension. (drugs.com)
  • PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated cancer of unknown primary. (mayo.edu)
  • However, the risk of toxicity is greater in this group than in patients with good performance status. (ersjournals.com)
  • OBJECTIVES: I. Evaluate the efficacy of paclitaxel and carboplatin with amifostine on progression free survival and overall survival in patients with metastatic or recurrent epithelial endometrial carcinoma not amenable to surgery or radiotherapy. (knowcancer.com)
  • Assess the nature and degree of toxicity of this regimen in these patients. (knowcancer.com)
  • OUTLINE: Patients receive paclitaxel IV over 3 hours, then amifostine IV over 10 minutes, followed fifteen minutes later by carboplatin IV over 30-60 minutes on day 1. (knowcancer.com)
  • The current study tested this hypothesis by using low-dose, weekly paclitaxel in patients with recurrent or refractory NHL. (duke.edu)
  • CONCLUSIONS: In the current study, low-dose, weekly paclitaxel therapy was found to provide a well tolerated and less toxic approach to the treatment of refractory NHL, with encouraging responses noted in heavily pretreated patients. (duke.edu)
  • V. Focused evaluation of toxicities that are of interest for older patients including: peripheral neuropathy, fatigue, falls, emergency room visits, hospitalization, treatment modification and discontinuation. (iu.edu)
  • Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy. (cdc.gov)
  • Warnings and precautions associated with Jemperli include immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicity. (drugs.com)
  • Safety profile of docetaxel regimens includes toxicities, particularly a high risk of neutropenia and febrile neutropenia. (hindawi.com)
  • These improvements in outcome are very welcome, yet they do have associated substantial toxicities, especially a moderate-to-high risk of neutropenia or febrile neutropenia (FN) [ 8 ]. (hindawi.com)
  • Conclusion Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival. (nih.gov)
  • Administration of trastuzumab products can result in serious and fatal infusion reactions and pulmonary toxicity. (rxlist.com)
  • The initial dose of Herzuma is 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel and carboplatin ). (rxlist.com)
  • After this the investigators adopted a 3 weeks on, 1 week off approach that resulted in less intense hematological toxicity compared with the weekly regimen. (medpagetoday.com)
  • Working primarily in hospitals, outpatient care centers and physician offices, respondents reported that they collectively administered over 90 specific antineoplastic drugs in the past week, with carboplatin, cyclophosphamide and paclitaxel the most common. (cdc.gov)
  • Unlike standard radiosensitizing agents, Opaxio appears tumor selective and does not appear to enhance radiation toxicity to normal tissues. (salesandmarketingnetwork.com)
  • Paclitaxel is an effective chemotherapeutic agent which is extracted from the bark of Taxus brevifolia . (scialert.net)
  • 18 years with refractory or recurrent, aggressive NHL who were not considered curable with standard high-dose therapy received paclitaxel at a dose of 80 mg/m2 weekly for 5 weeks for 2 cycles. (duke.edu)
  • Scholars@Duke publication: Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. (duke.edu)
  • Due to low solubility and limited source of production, paclitaxel is not used alone in clinic. (scialert.net)
  • There is a significant decrease in the productivity of the drug development pipeline due to low drug solubility and high toxicity. (umd.edu)
  • Motor1 and 2 significantly increased the solubility of drugs from many different therapeutic fields, such as paclitaxel (anticancer), cinnarizine (antihistamine), and 17a-ethynyl estradiol (hormone). (umd.edu)
  • But questions about the combination and quality of life remain because the addition of bevacizumab increases the toxicity of the treatment. (medscape.com)
  • [ 3 ] The antineoplastic agent paclitaxel is a terpene derived from yew plant bark. (medscape.com)
  • The toxicity of antineoplastic drugs is well-documented. (cdc.gov)
  • Segmentation of Gastric Computerized Tomography Images under Intelligent Algorithms in Evaluation of Efficacy of Decitabine Combined with Paclitaxel in Treatment of Gastric Cancer. (cdc.gov)
  • Bioactivity assays using anticancer drugs paclitaxel albendazole, camptothecin and PBS-1086 complexed in Motor1 resulted in significant cytotoxicity in HeLa cells. (umd.edu)
  • Toxicities were limited to diarrhea and neurotoxicity in 1 patient each. (jcancer.org)
  • Paclitaxel protein bound is a microtubular inhibitor (albumin-conjugated formulation) and a natural taxane that prevents depolymerization of cellular microtubules, which results in DNA, RNA, and protein synthesis inhibition. (medscape.com)
  • Once inside the tumor cell, enzymes metabolize the protein polymer, releasing active paclitaxel. (salesandmarketingnetwork.com)
  • Synthesis and toxicity evaluation in breast cancer cell lines. (lu.se)
  • Although high-dose taxanes have not been reported to be very effective for the treatment of lymphoma, different delivery rates may allow for different mechanisms of action to be manifest and result in a different toxicity profile and response rate. (duke.edu)
  • The GOG-0212 study is a randomized, multicenter, open label Phase 3 trial of either monthly Opaxio or paclitaxel for up to 12 consecutive months compared to surveillance among women with advanced ovarian cancer who have no evidence of disease following first-line platinum-taxane based therapy. (salesandmarketingnetwork.com)
  • This strategy was used to synthesize a series of spiro-bicyclic compounds designed to be paclitaxel mimetics, which were evaluated in human breast-derived cell lines. (lu.se)
  • In addition, two other spiro-bicyclic compounds, lacking the paclitaxel side chain, showed toxicity. (lu.se)
  • This coupled with host toxicity and drug bioactivity data indicate that these CB[n]-type compounds may be invaluable contributions to the toolbox of excipients and DDSs currently available. (umd.edu)
  • Toxicity was not different between treatment arms, and no unexpected safety signals emerged. (nih.gov)
  • No difference in toxicity was observed in the control or treatment groups. (researchgate.net)
  • A case report described camphor toxicity in a 35-year-old Cambodian man with diarrhea, vomiting, and altered mental status. (medscape.com)
  • Despite their efficiency, adoptive T-cell therapies show unique toxicities, which are distinct from those seen with conventional chemotherapies, monoclonal antibodies (mAbs), and small-molecule-targeted therapies. (nature.com)
  • The recognition of toxicity is of utmost importance as the use of these therapies increases. (nature.com)
  • Paclitaxel is one of the most important anti-cancer agents introduced during the last 20 years. (lu.se)
  • Cite this: DART Can Limit Toxicities in Head, Neck Cancer - Medscape - Oct 09, 2023. (medscape.com)
  • Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. (medscape.com)
  • Either increases toxicity of the other by pharmacodynamic synergism. (medscape.com)
  • Exposure to topical products that contain camphor can cause serious toxicity in young chlidren. (medscape.com)
  • However, the use of paclitaxel is limited by undesirable side effects as well as the development of drug resistance. (lu.se)